Compare · BSTC vs KIN
BSTC vs KIN
Side-by-side comparison of BioSpecifics Technologies Corp (BSTC) and Kindred Biosciences, Inc. (KIN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSTC and KIN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- KIN carries a market cap of $420.5M.
- Company
- BioSpecifics Technologies Corp
- Kindred Biosciences, Inc.
- Price
- -
- $9.25+0.00%
- Market cap
- -
- $420.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2013
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.
Latest BSTC
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- SEC Form 1 filed
- Endo Completes Acquisition of BioSpecifics
- Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
- WeissLaw LLP Reminds BSTC, DNKN, NAV, and PNM, Shareholders About Its Ongoing Investigations
- Lifshitz Law Firm, P.C. Announces Investigation of BioSpecifics Technologies Corp., Cleveland BioLabs, Inc., Concho Resources Inc., CONSOL Energy Inc., CONSOL Coal Resources LP, Endurance International Group Holdings, Inc., GCI Liberty, Inc., Liberty Broadband Corporation, and PNM Resources, Inc.
- WeissLaw LLP Reminds BSTC, PNM, and DNKN Shareholders About Its Ongoing Investigations
- Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
- BioSpecifics Reports Third Quarter 2020 Financial and Operating Results
Latest KIN
- TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors
- SEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)
- SEC Form 4 filed by Park West Asset Management Llc
- SEC Form 15-12B filed by Kindred Biosciences, Inc.
- SEC Form EFFECT filed by Kindred Biosciences, Inc.
- SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)
- SEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Bevers Denise returned $1,348,974 worth of Common Stock to the company (145,835 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Zhan Hangjun returned $594,830 worth of Common Stock to the company (64,306 units at $9.25), closing all direct ownership in the company